Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide
Bioventus, a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.
Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One®.1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ, to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA ® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.
“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
*DUROLANE SJ is not available in the US.
Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.
NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.
1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol. 2019;37 Suppl 120(5):3-6.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005067/en/
Contact information
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Relaunches Company Magazine CATch UP to Showcase the Best of the Brand12.11.2025 11:00:00 EET | Press release
Sports company PUMA has relaunched its online company magazine CATch UP to provide journalists, investors, retailers, athletes and sports enthusiasts with a window into the world of PUMA and insights into the company’s new strategic priorities, as the brand starts its transformation journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112815459/en/ Sports company PUMA has relaunched its online company magazine CATch UP to provide journalists, investors, retailers, athletes and sports enthusiasts with a window into the world of PUMA and insights into the company’s new strategic priorities, as the brand starts its transformation journey. The online magazine, which is available on puma-catchup.com, has received a thorough visual makeover and will focus on the stories that highlight the company’s innovations, sports, history, corporate culture and the strategic priorities that are being implemented to establish PUMA as a T
CWAN Report: Insurance Industry’s $2.7 Trillion Shift to Alternative Investments Creates Technology Gap12.11.2025 11:00:00 EET | Press release
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today released industry research revealing that alternative investments have fundamentally transformed from a fringe strategy to a portfolio cornerstone, now comprising nearly one-third of the US insurance industry’s assets – representing approximately $2.7 trillion – as insurers abandon traditional portfolio strategies. Similar structural shifts are also emerging across the UK and continental Europe as insurers pursue diversification, yield and liability-matching under Solvency II and evolving capital rules. The report, “Are ‘Alternatives’ Still Alternative?”, combines industry-wide NAIC data with analysis of approximately 400 CWAN insurers representing $4.4 trillion in combined assets, including UK and European insurers on the CWAN platform, providing granular insight into alternative investment adoption patterns across the insurance sector. CWAN’s Key Data Findings Challenge Indu
INNIO to Power UK Grid Stability with Landmark Project Near London12.11.2025 10:00:00 EET | Press release
INNIO Group and Clarke Energy are helping to deliver one of the world’s largest high-speed gas engine peaking power plants in Thurrock, England. The two companies already signed a contract to this effect in 2024. The 450-MW flexible generation facility is being constructed by Statera Energy, a leading developer, owner, and operator of flexible energy assets. With full operations targeted for late 2026, it is expected to provide enough power for up to 1 million homes in Southeast England—helping to support the UK’s energy resilience strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112767813/en/ Thurrock Flexible Generation Project (c) Statera Energy As the UK transitions to renewables, grid stability is more critical than ever. The Thurrock Flexible Generation Project is designed to respond rapidly to fluctuations in supply and demand, ensuring reliable electricity during peak periods and when renewable output vari
Visa Direct Stablecoin Payouts Pilot Speeds Up Access to Funds for Creators & Gig Workers12.11.2025 10:00:00 EET | Press release
At Web Summit today, Visa Inc. (V) announced a breakthrough pilot allowing businesses and platforms to send payouts directly to recipients’ stablecoin wallets. For businesses using Visa Direct, payouts can be funded in fiat currency, while recipients can choose to receive their funds in USD-backed stablecoins like USDC, transforming the speed and accessibility of global payouts. This innovation expands the reach of Visa Direct by providing creators, freelancers, and marketplaces with a stable store of value and faster access to funds - even in markets facing currency volatility or limited banking infrastructure. “Launching stablecoin payouts is about enabling truly universal access to money in minutes - not days - for anyone, anywhere in the world,” said Chris Newkirk, President, Commercial & Money Movement Solutions, Visa. “Whether it’s a creator building a digital brand, a business reaching new global markets or a freelancer working across borders, everyone benefits from faster, more
Ant International Launches World’s First Iris Authentication Feature in Smart-glasses Payment Solution12.11.2025 09:48:00 EET | Press release
In a global first, Ant International, a leading global digital payment, digitisation, and financial technology provider, has added iris authentication features to Alipay+ GlassPay, its AR glasses-embedded payment solution, through partnerships with leading smart glasses producers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111892620/en/ The enhanced solution improves consumer checkout experience and merchant payment success rate, and opens a new channel for personalised customer interaction Currently, Alipay+ GlassPay integrates multi-modal biometric verification measures including the AI-powered voice interface with intent recognition and voiceprint authentication technology. With the new feature successfully tested on AlipayHK, Alipay+ GlassPay now enables merchants and service providers to create an even smoother, more secure, and more immersive consumer experience via augmented reality. Using the latest innovation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom